Julie Vetalice, Author at ORTHOWORLD

Vericel Submits BLA to FDA for MACI for Treatment of Knee Cartilage Defects

Vericel submitted a Biologics License Application to FDA for MACI™ matrix applied characterized autologous cultured chondrocytes, an investigational product intended to treat adult symptomatic cartilage defects of the knee.

Jan 04, 2016

Extremities Market Attracts New Players and Innovation

Competitive Landscape Market Drivers

The extremities market generated worldwide product sales of $6.7 billion in 2014, a 9.5% year-over-year increase driven by the absence of payor scrutiny and company saturation, as well as heightened interest from surgeons and patients, according to ORTHOWORLD estimates.

Oct 01, 2015